Cambrex Reports Third Quarter 20...(68.2% 42057 74.5% ...),Health

Date:11/3/2009

68.2% 42,057 74.5% ------- ------- Gross Profit 16,948 29.3% 16,235 28.7% Operating Expenses Selling, General and Administrative Expenses 9,295 16.1% 8,767 15.5% Research and Development Expenses 2,026 3.5% 1,772 3.1% Restructuring Expenses - 0.0% 321 0.6% Strategic Alternative Costs - 0.0% 833 1.5% ------- ------- Total Operating Expenses 11,321 19.6% 11,693 20.7% ------- ------- Operating Profit 5,627 9.7% 4,542 8.0% Other Expenses/(Income): Interest Expense, net 1,111 1.9% 956 1.7% Other (Income)/Expense, net (31) -0.1% 485 0.8% ------- ------- Income Before Income Taxes 4,547 7.9% 3,101 5.5% Provision for Income Taxes 1,584 2.8% 304 0.6% ------- ------- Net Income $2,963 5.1% $2,797 4.9% ======= ======= Earnings per Share of Common Stock Basic $0.10 $0.10 Diluted $0.10 $0.10 Weighted Average Shares Outstanding Basic 29,253 29,163 Diluted 29,303 29,178 CAMBREX CORPORATION Statement of Profit and Loss For the Nine Months Ended September 30, 2009 and 2008 (in thousands) 2009 200
'/>"/>

SOURCE Cambrex Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA